NeuroDerm, Ltd.
http://www.neuroderm.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NeuroDerm, Ltd.
Quality Issues Star In US FDA Complete Response Letter Trio
Rocket Pharmaceuticals’ gene therapy Kresladi, Daiichi Sankyo/Merck’s patritumab deruxtecan, and AbbVie’s foscarbidopa/foslevodopa (ABBV-951) received CRLs because of manufacturing concerns.
US R&D Setbacks For Multiple Japanese Firms
Several Japanese firms are facing R&D challenges and setbacks in the US, in the form of missed Phase III endpoints, trial recruitment difficulties and a Complete Response Letter.
US FDA’s June Approvals Forecast: Nearly 30 Goal Dates Suggest Hot Start To Summer
June goal dates include RSV and pneumococcal vaccines, two COPD therapies, Rocket and Sarepta gene therapies, and lots of oncology.
Spotlight On Israel: Accessing Private Cash For Novel Technologies
Israel's appetite for biopharma investment is growing, but competition for cash is still tough and local investors are not only looking at regional startups to place their bets on.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice